Arbutus Biopharma Corporation ABUS Collaborations and licenses — Revenue

Other product segments

Similar metrics at other companies

RXSTLicense And Collaboration Revenue — Revenue

$6.5M—

FDMTCollaboration And License Revenue — Revenue

$3.05M+21,664%

PTCTCollaboration And License Revenue — Revenue

$143K-100.0%

KURALicense And Collaboration Revenue — Revenue

$12.5M-11.4%

EYPTLicense And Collaboration Agreement — Revenue

$507K-90.5%

AUPHLicense, collaboration and royalty revenue — Revenue

$3.81M+10.9%

FAQ

What is Arbutus Biopharma Corporation's collaborations and licenses — revenue?

Arbutus Biopharma Corporation (ABUS) reported collaborations and licenses — revenue of $204K in Q1 2026.

How has Arbutus Biopharma Corporation's collaborations and licenses — revenue changed year-over-year?

Arbutus Biopharma Corporation's collaborations and licenses — revenue decreased by 84.5% year-over-year, from $1.32M to $204K.

What is the long-term trend for Arbutus Biopharma Corporation's collaborations and licenses — revenue?

Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's collaborations and licenses — revenue has grown at a 26.8% compound annual growth rate (CAGR), from $4.88M to $12.6M.

What does collaborations and licenses — revenue mean?

This metric represents the total revenue recognized from strategic partnerships, research collaborations, and the licensing of proprietary intellectual property or technology platforms. It reflects the company's ability to monetize its research and development pipeline and specialized technical assets through third-party agreements. Fluctuations in this metric typically indicate the timing of milestone achievements, royalty payments, or the initiation of new commercial licensing deals.